Provided by Tiger Trade Technology Pte. Ltd.

Invesco S&P SmallCap Health Care ETF

52.87
-0.6339-1.18%
Post-market: 52.930.0561+0.11%16:15 EDT
Volume:7K
Turnover:393.37K
Market Cap:183.47M
PE:- -
High:53.12
Open:53.00
Low:52.81
Close:53.51
52wk High:56.45
52wk Low:39.08
Shares:3.47M
Float Shares:3.47M
Volume Ratio:0.24
T/O Rate:0.21%
Dividend:0.00
Dividend Rate:0.01%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness

Reuters
·
Aug 05

Ultragenyx Q2 Revenue Rises 28% to Record High, Net Loss Narrows

Reuters
·
Aug 05

Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $98,821.72

Reuters
·
Aug 04

Corcept CFO Atabak Mokari Sells 79,000 Shares Worth $8.95 Million

Reuters
·
Aug 04

Fresenius announces FDA approval of rituximab biosimilar

TIPRANKS
·
Aug 04

ClearPoint Neuro Q2 Revenue Rises 18% but Misses Estimates

Reuters
·
Aug 04

GeneDx Q2 Revenue Beats Analyst Estimates

Reuters
·
Aug 04

Alkermes Amends 8-K to Disclose CEO Blair Jackson Pay Package Including $5 Million Equity Award

Reuters
·
Aug 04

Krystal Biotech Down Nearly 12%, on Pace for Largest Percent Decrease Since August 2025

Dow Jones
·
Aug 04

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 04

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 03

Krystal Biotech Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 03

Design Therapeutics Q2 Net Loss Narrower than Expected

Reuters
·
Aug 03

Ocular Therapeutix Q2 Product Revenue Flat, Net Loss Widens on Higher Spending

Reuters
·
Aug 03

Brightspring Health Services Inc : Raymond James Cuts Target Price to $75 from $80

THOMSON REUTERS
·
Aug 03

Krystal Biotech Q2 Revenue Rises on Vyjuvek Strength

Reuters
·
Aug 03

Krystal Biotech Shares Down 5.8% Premarket After Q2 Results

THOMSON REUTERS
·
Aug 03

Krystal Biotech Q2 Net Income Rises 43% to $54.8 Million; Revenue Climbs 24% to $119.2 Million

Reuters
·
Aug 03

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

THOMSON REUTERS
·
Aug 03

Krystal Biotech - Sees FY 2026 Non-Gaap R&D and SG&a Expense $175 Mln-$195 Mln

THOMSON REUTERS
·
Aug 03